medigraphic.com
Revista Médica Sinergia

2021, Number 01

<< Back Next >>

Revista Médica Sinergia 2021; 6 (01)

Practical insulinization in type 2 diabetes mellitus

Blanco NEG, Chavarría CGF, Garita FYM

Language: Spanish
References: 23
Page: 1-11
PDF size: 238.10 Kb.


ABSTRACT

Type 2 diabetes mellitus is characterized as a chronic disease of a progressive nature, with a state of hyperglycemia and varying degrees of insulin deficiency and resistance. Education and support for diabetes selfcontrol are critical to prevent acute complications and reduce the risk of long term complications. Insulinization therapy has been an effective aid to improve the long-term control and quality of life of patients with type 2 diabetes mellitus. There are two large groups of insulins that are human insulins and insulin analogues. The former has determined to be an effective and less expensive option, for this reason doctors should be familiar with its use. They can use various schemes for insulin, the basal scheme is the one that has the greatest reduction in glycemic levels and lower risk of hypoglycemia. It is also simple which facilitates the adherence of patients to treatment.


REFERENCES

  1. Mora G, Martín D, Moreno I, Jerez B, Puerto M, Cabral R. Insulinización temprana como una herramienta eficaz para mejorar el control metabólico del paciente diabético. ¿Cuándo? ¿Cómo? ¿Con qué?. Diabetes Práctica RedGDPS. 2017;8(Supl Extr 4): 1-24. https://doi.org/10.26322/2013.7923.1505400426.03

  2. Lagunes R, Galindo I, Castillo A, Romero C, Rosas F. ¿Por qué los médicos no utilizan en forma temprana la insulinización en pacientes con diabetes mellitus tipo 2?: Un estudio cualitativo en una ciudad mexicana. Salud Colectiva. 2017;13(4):693. https://doi.org/10.18294/sc.2017.1341

  3. Alemán J, Artola S, Ávila L, Barrot J, Barutell L, Benito B et al. Guía de diabetes tipo 2 para clínicos. Recomendaciones de la redGDPS [Internet]. 2018 [cited 8 February 2020];(1). Available from: https://www.redgdps.org/guia-de-diabetes-tipo-2-para-clinicos

  4. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S14-S31. https://doi.org/10.2337/dc20-S002

  5. Díaz Naya, L., & Delgado Álvarez, E. (2016). Diabetes mellitus. Criterios diagnósticos y clasificación. Epidemiología. Etiopatogenia. Evaluación inicial del paciente con diabetes. Medicine - Programa de Formación Médica Continuada Acreditado, 12(17), 935–946. https://doi.org/10.1016/j.med.2016.09.001

  6. Wexler D. Insulin therapy in type 2 diabetes mellitus. UpToDate Inc [Internet]. 2019 [cited 3 March 2020];. Available from: https://www.uptodate.com/contents/insulin-therapy-in-type-2-diabetes-mellitus

  7. Aguirre J, Hidalgo A, Mene M, Enguix D, Benayas A, Garcia M. Grado de control cardiovascular en pacientes diabéticos tipo 2 de acuerdo con objetivos individualizados: Estudio “CONCARDIA”. Sociedad Española de Médicos Generales y de Familia. 2018;7(4):140-145 http://dx.doi.org/10.24038/mgyf.2018.050

  8. American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S66–S76 https://doi.org/10.2337/dc20-S006

  9. McCulloch D, Hayward R. Screening for type 2 diabetes mellitus. UpToDate Inc [Internet]. 2019 [cited 3 March 2020];. Available from: https://www.uptodate.com/contents/screening-for-type-2-diabetes-mellitus

  10. Rodríguez-Lay E, Michahelles C. Análogos de insulina de acción prolongada versus insulina NPH en diabetes mellitus. Rev Soc Peru Med Interna. 2018;31(2):104-109. http://medicinainterna.net.pe/sites/default/files/revista_vol_23_3/SPMI%202018- 3%20Analogos%20de%20insulina%20de%20accion%20prolongada%20vs%20insulina%20NPH%20en%20diab etes.pdf

  11. Mata M. Tipos de insulina. Diabetes Práctica RedGDPS. 2017;8(Supl Extr 4):1-24. https://doi.org/10.26322/2013.7923.1505400426.03

  12. INFAC. Actualzación de insulina. Boletín INFAC [Internet]. 2017 [cited 3 March 2020];25(3):22-30. Available from: https://www.fundacionfemeba.org.ar/blog/farmacologia-7/post/actualizacion-de-insulinas-44559

  13. Lipska K, Parker M, Moffet H, Huang E, Karter A. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2018;320(1):53. https://doi.org/10.1001/jama.2018.7993

  14. Lipska K, Hirsch I, Riddle M. Human Insulin for Type 2 Diabetes. JAMA. 2017;318(1):23. https://doi.org/10.1001/jama.2017.6939

  15. Machado J, Medina D, Echeverri L. Comparison of medication adherence in diabetes mellitus patients on human versus analogue insulins. Expert Opinion on Drug Safety. 2016;1(1):1-5. http://dx.doi.org/10.1080/14740338.2017.1273346

  16. Girbés J, Escalada J, Mata M, Gomez F, Artola S, Fernández D et al. Consenso sobre tratamiento con insulina en la diabetes tipo 2. Endocrinología, Diabetes y Nutrición. 2018;65(1):1-8. https://doi.org/10.1016/j.endinu.2018.01.002

  17. Gomez F, Escalada F, Menéndez E, Mata M, Ferrer J, Ezkurra P et al. Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018. Endocrinología, Diabetes y Nutrición. 2018;65(10):611-624. https://doi.org/10.1016/j.endinu.2018.08.004

  18. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2019;43(Supplement 1):S98-S110. https://doi.org/10.2337/dc20-S009

  19. McCulloch D. General principles of insulin therapy in diabetes mellitus. UpToDate Inc [Internet]. 2019 [cited 3 March 2020];. Available from: https://www.uptodate.com/contents/general-principles-of-insulin-therapy-indiabetes- mellitus

  20. Fuente G, Sinay I, Costa J, Puchulu F, Dieuzeide G, Rodriguez M et al. Insulinización en la diabetes mellitus tipo 2: Alternativas de intensificación. Medicina (Buenos Aires) [Internet]. 2016 [cited 29 February 2020];76(1):173 -179. Available from: https://www.researchgate.net/publication/317532245_Insulinizacion_en_la_diabetes_mellitus_tipo_2_Alternativa s_de_intensificacion

  21. Chien M, Chen Y, Hung Y, Wang S, Lu W, Chen C et al. Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2016;7(6):881-888. https://doi.org/10.1111/jdi.12532

  22. Chacón F, Agobian G, Ramos M, Rangel L, Alvarado J, Adamek P et al. Eficacia del esquema de terapia de insulina basal/bolo vs basal/plus en pacientes diabéticos tipo 2. ResearchGate [Internet]. 2016 [cited 3 March 2020];32(1):2-7. Available from: https://www.researchgate.net/publication/314078004_EFICACIA_DEL_ESQUEMA_DE_TERAPIA_DE_INSULIN A_BASALBOLO_VS_BASALPLUS_EN_PACIENTES_DIABETICOS_TIPO_2

  23. Downie M, Kilov G, Wong J. Initiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix Regimens. Diabetes Therapy. 2016;7(4):641-657. https://doi.org/0.1007/s13300-016-0199-2




2020     |     www.medigraphic.com